World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
65
Citations
34396
World Ranking
8928
National Ranking
274

Overview

Jifeng Feng is affiliated with Nanjing Medical University in China. Their research work spans broadly across the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on Oncology and Pulmonary and Respiratory Medicine. Subfields of study include Molecular Biology, Cancer Research, and Pathology and Forensic Medicine.

The scientist's research primarily addresses topics related to Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Advanced Breast Cancer Therapies, Lymphoma Diagnosis and Treatment, Colorectal Cancer Treatments and Studies, and HER2/EGFR in Cancer Research.

Frequent publication venues for Jifeng Feng include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Research Square (Research Square)
  • Frontiers in Oncology
  • Journal of Thoracic Oncology

Among the recent papers featuring Jifeng Feng's research are:

  • Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Respiratory Medicine
  • Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11), 2020, Journal of Thoracic Oncology
  • Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02), 2021, Journal of Clinical Oncology
  • AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations, 2022, Journal of Clinical Oncology

Collaborations form a significant part of their work, with frequent coauthors including Jian Wu, Ying Cheng, Qingyuan Zhang, Jianying Zhou, and Yuankai Shi.

Best Publications

  • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

    Ann Lii Cheng;Yoon Koo Kang;Zhendong Chen;Chao Jung Tsao

  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

    Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

    Yi-Long Wu;Caicun Zhou;Cheng-Ping Hu;Jifeng Feng

  • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  • Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

    Yuankai Shi;Li Zhang;Xiaoqing Liu;Caicun Zhou

  • Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

    Jonathan W Goldman;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial

    Huiyan Luo;Huiyan Luo;Jin Lu;Yuxian Bai;Teng Mao

  • BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

    Caicun Zhou;Yi-Long Wu;Gongyan Chen;Xiaoqing Liu

  • Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

    Caicun Zhou;Gongyan Chen;Yunchao Huang;Jianying Zhou

  • Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

    Fei Ma;Quchang Ouyang;Wei Li;Zefei Jiang

  • Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).

    Yunpeng Yang;Zhehai Wang;Jian Fang;Qitao Yu

  • Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

    Binghe Xu;Min Yan;Fei Ma;Xichun Hu

  • Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.

    Yi Long Wu;Shun Lu;Ying Cheng;Caicun Zhou

  • Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Zefei Jiang;Wei Li;Xichun Hu;Qingyuan Zhang

  • Tumor-derived exosomes in cancer progression and treatment failure

    Shaorong Yu;Haixia Cao;Bo Shen;Jifeng Feng

  • Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).

    Feng-Hua Wang;Xiao-Li Wei;Jifeng Feng;Qi Li

  • Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin.

    Xia Xiao;Shaorong Yu;Shuchun Li;Jianzhong Wu

  • Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.

    Xiaobing Qin;Shaorong Yu;Leilei Zhou;Meiqi Shi

Frequent Co-Authors

Caicun Zhou
Caicun Zhou Tongji University
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Li Zhang
Li Zhang Sun Yat-sen University
Yongqian Shu
Yongqian Shu Nanjing Medical University
Igor Bondarenko
Igor Bondarenko Ministry of Internal Affairs
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Tony Mok
Tony Mok Chinese University of Hong Kong
Lecia V. Sequist
Lecia V. Sequist Harvard University
Wu Chou Su
Wu Chou Su National Cheng Kung University
Rui-Hua Xu
Rui-Hua Xu Sun Yat-sen University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Biology and Biochemistry in the USA can lead to diverse and rewarding career opportunities, many of which can be furthered with online education. For those interested in mental health, psychiatric np programs offer a fast, flexible route to advanced nursing roles focused on psychiatric care.

If you’re passionate about health and wellness, earning a fast track nutrition degree can help position you for roles in clinical nutrition, public health, or wellness coaching. Online programs allow you to complete coursework at your own pace, often accelerating your entry into the workforce.

For students drawn to the business side of healthcare, an affordable online mba in healthcare management can open doors to leadership positions in hospitals, clinics, and biotech companies. These practical MBA programs are ideal for working professionals seeking advancement.

Lastly, those considering careers in medical coding and administration can compare ccs vs cpc certifications. Understanding the differences between these credentials can help you choose the right certification for your career goals and salary expectations in healthcare administration.

Best Scientists Citing Jifeng Feng

Trending Scientists